Vaccination and ivermectin

Novavax, 14th June, NVX-CoV2373 Recombinant nanoparticle protein-based COVID-19 vaccine Soapbark tree Influenza and HPV Fridge, 2 doses, 3 week gap Placebo-controlled, double blind, randomized 2:1 100% protection against moderate and severe disease All hospitalizations and deaths in placebo group 90.4% efficacy overall 91% efficacy in high-risk populations (over 65 or comorbidities) N = 29,960, 119 sites, U.S. and Mexico File for regulatory authorizations in the third quarter 100 million doses per month, then 150 million per month by end of 2021 UK, with GlaxoSmithKline, 60 million doses, Barnard Castle Results: Consistent, high efficacy among circulating variants 77 infections Placebo group,